/person/borsatti-alessandro-agilent-201409-technologies-diagnostics-genomics-group-2001-13688.html
 
 
 
 

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px
Person › Details

Alessandro Borsatti (Agilent Technologies, Diagnostics and Genomics Group (DGG))

Borsatti, Alessandro (Agilent 201409 Senior Director of Marketing Diagnostics + Genomics Solutions Group)

 

Organisation Organisation Agilent Technologies, Diagnostics and Genomics Group (DGG)
Products Product genomic technology
  Product 2 diagnostics (medical/biological)
     

Agilent Technologies Inc.. (9/4/14). "Press Release: Agilent Technologies Introduces Tools for Next-generation Genome Engineering. SureGuide Kits Represent First Integrated Solution for In-vitro CIRSPR/Cas9 Research". Santa Clara, CA.

Agilent Technologies Inc. (NYSE: A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.

The complete SureGuide workflow includes a SureGuide Cas9 Nuclease Kit, SureGuide gRNA Synthesis Kit and SureGuide gRNA Control Kit, all designed to work together for any lab interested in quickly enabling next-generation genome engineering. The workflow represents the first integrated solution for in-vitro CRISPR/Cas9 experiments, with gRNA design and gRNA synthesis, and is available as a kit or as individual components.

The SureGuide family of tools will enable in-vitro cloning of large genes or complex DNA mixtures without the limitations imposed by common restriction enzymes or PCR fidelity. With SureGuide, scientists can cleave DNA at single and multiple locations, and rapidly alter target regions with minimal effort. The SureGuide gRNA synthesis kit integrates highly efficient synthesis with an optimized purification step in a streamlined protocol.

"SureGuide provides a simple, integrated tool set designed to expand access to this remarkable technology by making it easier for scientists to integrate CRISPR/Cas9 in their everyday cloning workflows," said Alessandro Borsatti, senior director of Marketing for Agilent's Diagnostics and Genomics Solutions Group. "SureGuide enables truly programmable, customizable cloning specificity while improving on the efficiency scientists expect from current nuclease technologies."

SureGuide kits provide the easiest and fastest integrated solution for scientists looking to benefit from the advances in CRISPR/Cas technology by adding this technique to their workflow. SureGuide is the first in a series of products from Agilent that will continue to enable new applications in genome editing and engineering. It will be followed by the release of other products specifically targeted to synthetic biology and functional genomics.

Click here to learn more about Agilent's SureGuide family of products.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company's electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.


Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent's electronic measurement business; future revenues, earnings and profitability; the future demand for the company's products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

# # #

Contact:

Susan Berg
+1 408 553 7093
susan_berg1@agilent.com

   
Record changed: 2017-04-09

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px


More documents for Alessandro Borsatti


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px




» top